CHA Vaccine Research Institute (KOSDAQ: 261780)
South Korea
· Delayed Price · Currency is KRW 3,170.00
-90.00 (-2.76%)
Dec 19, 2024, 12:45 PM KST
CHA Vaccine Research Institute Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Operating Revenue | 370.66 | 294.12 | 179.48 | 500 | 77.8 | 126.11 | Upgrade
|
| Other Revenue | -0 | -0 | -0 | - | - | -0 | Upgrade
|
| Revenue | 370.66 | 294.12 | 179.48 | 500 | 77.8 | 126.11 | Upgrade
|
| Revenue Growth (YoY) | 26.02% | 63.87% | -64.10% | 542.70% | -38.31% | -27.24% | Upgrade
|
| Cost of Revenue | 23.93 | 34.5 | 19 | - | 13.01 | 39.97 | Upgrade
|
| Gross Profit | 346.73 | 259.62 | 160.49 | 500 | 64.79 | 86.14 | Upgrade
|
| Selling, General & Admin | 1,968 | 2,197 | 2,357 | 3,199 | 1,038 | 468.82 | Upgrade
|
| Research & Development | 4,975 | 3,949 | 3,855 | 3,140 | 3,124 | 2,458 | Upgrade
|
| Operating Expenses | 7,494 | 6,679 | 6,630 | 6,585 | 4,299 | 2,960 | Upgrade
|
| Operating Income | -7,147 | -6,419 | -6,469 | -6,085 | -4,234 | -2,874 | Upgrade
|
| Interest Expense | -1,370 | -2,631 | -2,567 | -2,122 | -837.2 | -537.32 | Upgrade
|
| Interest & Investment Income | 1,675 | 2,282 | 1,017 | 179.88 | 77.17 | 57.22 | Upgrade
|
| Currency Exchange Gain (Loss) | 10.02 | 2.67 | 0.02 | 0.17 | 0.04 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 2,382 | 4,703 | 1,198 | -10,520 | -1,278 | 326.79 | Upgrade
|
| EBT Excluding Unusual Items | -4,450 | -2,063 | -6,821 | -18,546 | -6,272 | -3,028 | Upgrade
|
| Gain (Loss) on Sale of Investments | -163.74 | -40.4 | 105.84 | 125.77 | 31.7 | 47.4 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 0.32 | -0.01 | Upgrade
|
| Pretax Income | -4,614 | -2,103 | -6,715 | -18,420 | -6,240 | -2,980 | Upgrade
|
| Income Tax Expense | -353.77 | -353.77 | - | - | - | - | Upgrade
|
| Net Income | -4,260 | -1,749 | -6,715 | -18,420 | -6,240 | -2,980 | Upgrade
|
| Net Income to Common | -4,260 | -1,749 | -6,715 | -18,420 | -6,240 | -2,980 | Upgrade
|
| Shares Outstanding (Basic) | 27 | 27 | 26 | 23 | 18 | - | Upgrade
|
| Shares Outstanding (Diluted) | 27 | 27 | 26 | 23 | 18 | - | Upgrade
|
| Shares Change (YoY) | 0.35% | 0.69% | 13.39% | 30.03% | - | - | Upgrade
|
| EPS (Basic) | -159.50 | -65.72 | -254.00 | -790.00 | -348.00 | - | Upgrade
|
| EPS (Diluted) | -159.50 | -65.72 | -254.00 | -790.00 | -348.00 | - | Upgrade
|
| Free Cash Flow | -6,356 | -5,572 | -5,636 | -5,419 | -4,007 | -3,217 | Upgrade
|
| Free Cash Flow Per Share | -237.97 | -209.32 | -213.18 | -232.42 | -223.48 | - | Upgrade
|
| Gross Margin | 93.54% | 88.27% | 89.42% | 100.00% | 83.28% | 68.30% | Upgrade
|
| Operating Margin | -1928.25% | -2182.53% | -3604.36% | -1216.93% | -5442.95% | -2279.13% | Upgrade
|
| Profit Margin | -1149.35% | -594.82% | -3741.36% | -3684.01% | -8021.37% | -2363.12% | Upgrade
|
| Free Cash Flow Margin | -1714.84% | -1894.38% | -3140.08% | -1083.82% | -5151.23% | -2550.66% | Upgrade
|
| EBITDA | -6,596 | -5,886 | -6,052 | -5,839 | -4,094 | -2,840 | Upgrade
|
| D&A For EBITDA | 550.87 | 533.31 | 417.36 | 245.49 | 140.16 | 34.48 | Upgrade
|
| EBIT | -7,147 | -6,419 | -6,469 | -6,085 | -4,234 | -2,874 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.